Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Biweekly cladribine and rituximab in a patient with hairy cell leukemia and severe renal failure. (CROSBI ID 309519)

Prilog u časopisu | kratko priopćenje | međunarodna recenzija

Ranković, Ena ; Dotlić, Snježana ; Rončević, Pavle ; Vodanović, Marijo ; Aurer, Igor Biweekly cladribine and rituximab in a patient with hairy cell leukemia and severe renal failure. // Clinical case reports and reviews, 6 (2020), 1-2. doi: 10.15761/CCRR.1000485

Podaci o odgovornosti

Ranković, Ena ; Dotlić, Snježana ; Rončević, Pavle ; Vodanović, Marijo ; Aurer, Igor

engleski

Biweekly cladribine and rituximab in a patient with hairy cell leukemia and severe renal failure.

Hairy cell leukemia (HCL) is a rare indolent lymphoproliferative disorder usually clinically characterized by pancytopenia and splenomegaly. It is very sensitive to purine analogues cladribine and pentostatin which are both primarily excreted by kidneys and registration labels bear warnings against their use in patients with severe renal insufficiency. We report a patient with HCL and severe renal failure who was successfully treated with five subcutaneous injections of cladribine 0.14 mg/ kg and six biweekly infusions of rituximab 375 mg/2 iv. This regimen was tolerated remarkably well without cumbersome side–effects. Our case- report suggests that cladribine can be efficaciously and safely used in patients with severe renal insufficiency if administered in standard doses once every two weeks.

hairy cell leukemia ; chronic renal failure ; cladribine ; rituximab

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

6

2020.

1-2

objavljeno

2059-0393

10.15761/CCRR.1000485

Povezanost rada

Kliničke medicinske znanosti

Poveznice